Malignant mixed Mullerian tumor

Search Trials
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Status:
Completed
Last Changed:
Jan 19, 2018
First Changed:
Jan 27, 2003
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
Laboratory Biomarker AnalysisThalidomide
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Aug 29, 2017
First Changed:
Nov 24, 2010
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
Pazopanib Hydrochloride
Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO – PazoDoble –
Status:
Unknown status
Last Changed:
Jul 30, 2014
First Changed:
Jul 30, 2014
Disease(s):
Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Intervention(s):
Pazopanib plus GemcitabinePazopanib
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Status:
Completed
Last Changed:
May 9, 2016
First Changed:
Jul 17, 2007
Disease(s):
Mixed Tumor, Mullerian
Intervention(s):
CarboplatinPaclitaxel
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Status:
Completed
Last Changed:
Aug 7, 2012
First Changed:
Jun 2, 2008
Disease(s):
Uterine Carcinosarcoma
Intervention(s):
paclitaxelcarboplatinBSI-201 (Iniparib)

Connect. Empower. Inspire.